Letter · 2022

Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials

Frédéric Fiteni

The Lancet Oncology, 23(11), e480 · Published 31 October 2022 · DOI 10.1016/s1470-2045(22)00628-3

View at the publisherCite this paper

In brief

“Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials” is a 2022 letter by Frédéric Fiteni, published in The Lancet Oncology. OpenAlex counts 0 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
References
3
Authors
1

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Fiteni, F. (2022). Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials. The Lancet Oncology, 23(11), e480. https://doi.org/10.1016/s1470-2045(22)00628-3

MLA 9

Fiteni, Frédéric. “Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials.” The Lancet Oncology, vol. 23, no. 11, 2022, p. e480. https://doi.org/10.1016/s1470-2045(22)00628-3.

Chicago

Fiteni, Frédéric. 2022. “Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials.” The Lancet Oncology 23 (11): e480. https://doi.org/10.1016/s1470-2045(22)00628-3.

Harvard

Fiteni, F. (2022) ‘Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials’, The Lancet Oncology, 23(11), p. e480. doi:10.1016/s1470-2045(22)00628-3.

IEEE

F. Fiteni, “Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials,” The Lancet Oncology, vol. 23, no. 11, p. e480, 2022, doi: 10.1016/s1470-2045(22)00628-3.

BibTeX

@article{fiteni2022appropriateness,
  title     = {{Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials}},
  author    = {Fiteni, Frédéric},
  journal   = {The Lancet Oncology},
  year      = {2022},
  volume    = {23},
  number    = {11},
  pages     = {e480},
  doi       = {10.1016/s1470-2045(22)00628-3},
  url       = {https://doi.org/10.1016/s1470-2045(22)00628-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment

  • ovarian cancer
  • clinical trial endpoints
  • survival
  • quality of life
  • toxicity
  • composite endpoints
  • consensus recommendations

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Fiteni, F. (2022). Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials. The Lancet Oncology, 23(11), e480. https://doi.org/10.1016/s1470-2045(22)00628-3

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Frédéric Fiteni.

What is the DOI of this paper?

10.1016/s1470-2045(22)00628-3, permanently at https://doi.org/10.1016/s1470-2045(22)00628-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.